Review on Molecular Mechanism of First Line Antibiotic Resistance in Mycobacterium tuberculosis

Debasu Damtie, D. Woldeyohannes, Biniam Mathewos
{"title":"Review on Molecular Mechanism of First Line Antibiotic Resistance in Mycobacterium tuberculosis","authors":"Debasu Damtie, D. Woldeyohannes, Biniam Mathewos","doi":"10.4172/2161-1068.1000174","DOIUrl":null,"url":null,"abstract":"Tuberculosis (TB) is among the most common infectious diseases and frequent causes of death worldwide claiming many of lives annually. The problem of tuberculosis is hampered by the emergence of multi drug resistant(MDR) and extensively drug resistant (XDR) tuberculosis. Anti-tuberculosis drugs are a two-edged sword. While they destroy pathogenic Mycobacterium tuberculosis they also select for drug resistant bacteria against which those drugs are then ineffective. \n In contrast to other bacteria, resistance of M. tuberculosis is exclusively associated with chromosomal mutations. Globally, the emergence of multidrug-resistant strains of M. tuberculosis is an increasing problem which adversely affects patient care and public health. The objective of this review is therefore to compile available literatures about the drug resistance mechanisms of M. tuberculosis which gives insight understanding for the development of new therapeutic and diagnostic methods for the management of MDR and XDR tuberculosis infections. \n Resistance to first line anti-TB drugs has been linked to mutations in at least 10 genes; katG, inhA, ahpC, kasA and ndh for INH resistance; rpoB for RIF resistance, embB for EMB resistance, pncA for PZA resistance and rpsL and rrs for STR resistance. The search for new anti-tuberculosis drugs shall consider new targets which are less susceptible for mutation.","PeriodicalId":74235,"journal":{"name":"Mycobacterial diseases : tuberculosis & leprosy","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2161-1068.1000174","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycobacterial diseases : tuberculosis & leprosy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-1068.1000174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

Tuberculosis (TB) is among the most common infectious diseases and frequent causes of death worldwide claiming many of lives annually. The problem of tuberculosis is hampered by the emergence of multi drug resistant(MDR) and extensively drug resistant (XDR) tuberculosis. Anti-tuberculosis drugs are a two-edged sword. While they destroy pathogenic Mycobacterium tuberculosis they also select for drug resistant bacteria against which those drugs are then ineffective. In contrast to other bacteria, resistance of M. tuberculosis is exclusively associated with chromosomal mutations. Globally, the emergence of multidrug-resistant strains of M. tuberculosis is an increasing problem which adversely affects patient care and public health. The objective of this review is therefore to compile available literatures about the drug resistance mechanisms of M. tuberculosis which gives insight understanding for the development of new therapeutic and diagnostic methods for the management of MDR and XDR tuberculosis infections. Resistance to first line anti-TB drugs has been linked to mutations in at least 10 genes; katG, inhA, ahpC, kasA and ndh for INH resistance; rpoB for RIF resistance, embB for EMB resistance, pncA for PZA resistance and rpsL and rrs for STR resistance. The search for new anti-tuberculosis drugs shall consider new targets which are less susceptible for mutation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结核分枝杆菌一线耐药分子机制研究进展
结核病是世界上最常见的传染病之一,也是每年夺去许多人生命的常见死因。结核病问题因耐多药结核病和广泛耐药结核病的出现而受到阻碍。抗结核药物是一把双刃剑。在它们摧毁致病性结核分枝杆菌的同时,它们也会选择耐药细菌,然后这些药物就无效了。与其他细菌不同,结核分枝杆菌的耐药性完全与染色体突变有关。在全球范围内,耐多药结核分枝杆菌菌株的出现是一个日益严重的问题,对患者护理和公共卫生产生不利影响。因此,本综述的目的是汇编有关结核分枝杆菌耐药机制的现有文献,为开发新的耐多药和广泛耐药结核感染的治疗和诊断方法提供深入的了解。对一线抗结核药物的耐药性与至少10个基因的突变有关;ktag、inhA、ahpC、kasA和ndh对INH的抗性;rpoB表示RIF抗性,embB表示EMB抗性,pncA表示PZA抗性,rpsL和rrs表示STR抗性。寻找新的抗结核药物应考虑不易突变的新靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Study of white rot fungi for the production of laccase and its multifold application To Study The Effect of Pesticide Resistant Azotobacter spp. For The Production of Biofertilizer Inbred Mouse Strain Susceptibility to Tuberculosis Infection Vary with Phenotype, the Dose of Infection, Obesity and Composition of the Intestinal Microbiome Recombinant antigens and synthetic peptides to characterize Mycobacterium tuberculosis proteins for immunological reactivity The potential of delayed type hypersensitivity-inducing Mycobacterium tuberculosis-specific antigens in the diagnosis of tuberculosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1